- Home
- RSVR vs SIGA Comparison
RSVR vs SIGA Comparison
Compare RSVR & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSVR | SIGA |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 462.6M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | RSVR | SIGA |
|---|---|---|
| Price | $7.38 | $6.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | 64.4K | ★ 366.8K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | ★ 8.86% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.15 | ★ 1.03 |
| Revenue | $166,320,844.00 | ★ $172,249,641.00 |
| Revenue This Year | $9.06 | N/A |
| Revenue Next Year | $5.37 | $132.36 |
| P/E Ratio | $50.04 | ★ $6.57 |
| Revenue Growth | ★ 11.17 | N/A |
| 52 Week Low | $6.56 | $4.95 |
| 52 Week High | $8.94 | $9.62 |
Technical Indicators
Market Signals| Indicator | RSVR | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 61.37 |
| Support Level | $7.33 | $6.08 |
| Resistance Level | $7.59 | $6.88 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 27.45 | 85.00 |
Price Performance
Historical ComparisonAbout RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.